Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

GCP aggregated data - Chemical perturbations

ABSTRACT: Global chromatin epigentic profiles of human cancer and NPC cell lines treated with neurodevelopmental compounds, epigenetic compounds and kinase inhibitors.

PROVIDER: LDS-41235 | LINCS | 2020-04-13

REPOSITORIES: LINCS

ACCESS DATA

Json Xml

Similar Datasets

GCP data - Chemical perturbations (MCF10A Common Project)

Project description:Global chromatin epigentic profiles of MCF10A cell line treated with 8 FDA-approved drugs.

2016-07-18 | LDS-1343 | LINCS

GCP aggregated data - CRISPR perturbations

Project description: Not available

2017-10-20 | LDS-1498 | LINCS

GCP - Selected chemical agents in schizophrenia patient-derived neural progenitor cells

Project description: Not available

| LDS-1521 | LINCS

GCP data - neurodev compounds

Project description:Global chromatin epigentic profiles of NPC cell lines treated with neurodevelopmental compounds.

2015-06-30 | LDS-1236 | LINCS

GCP data - epigenetic compounds

Project description:Global chromatin epigentic profiles of human cancer and NPC cell lines treated with epigenetic compounds.

2015-06-30 | LDS-1235 | LINCS

GCP data - kinase inhibitors

Project description:Global chromatin epigentic profiles of human cancer and NPC cell lines treated with kinase inhibitors.

2016-01-08 | LDS-1265 | LINCS

GCP - Drug treatment of vascular cell model systems

Project description: Not available

| LDS-1522 | LINCS

GCP data - Selected Cell Lines treated with an HSP90 inhibitor

Project description: Not available

| LDS-1520 | LINCS

Mapping Epigenomic Type-Specific Differences Occurring During Hematopoiesis

Project description:Formation of the blood from self-renewing hematopoietic stem cells to terminal lineages necessarily involves epigenomic modifications of the genome to control regulator and signature gene expression. By analysing the global expression profiles of hematopoietic stem cells (HSCs), in vivo differentiated CD4+ T cells and CD19+ B cells as well as in vitro differentiated erythrocyte precursor cells, we identified hundreds of transcripts showing type-specific expression in these cell types. To understand the epigenomic changes related to tissue-specific expression during HSC differentiation, we examined the genome-wide distribution of H3K4me1, H3K4me3, H3K27me1, H3K27me3, histone variant H2A.Z, chromatin remodeler BRG1, and RNA Polymerase II in the same four cell types, as well as embryonic stem cells. Analysis of these datasets revealed that numerous key differentiation genes are primed for expression by Brg1 and Pol II binding, as well as bivalent modifications in the HSCs prior to their expression in downstream differentiated cell types. Much of this bivalency in HSC is retained from embryonic stem cells. After differentiation, these modified regions resolve to active chromatin modification configuration in the specific lineage, while in parallel differentiated lineages the bivalent modification remains; Pol II and Brg1 are lost in closer lineages but bivalency resolves to silent monovalency in more distant lineages. Correlation of tissue-specific gene expression with the epigenomic changes predicts tens of thousands of potential common enhancers and tissue-specific enhancers, which may critically contribute to the expression patterns. We provide a valuable dataset for further understanding the regulatory mechanisms of differentiation and function of blood lineages. This SuperSeries is composed of the SubSeries listed below. Refer to individual Series.

2013-03-25 | E-GEOD-39229 | biostudies-arrayexpress

Mapping Epigenomic Type-Specific Differences Occurring During Hematopoiesis [ChIP-Seq]

Project description:Formation of the blood from self-renewing hematopoietic stem cells to terminal lineages necessarily involves epigenomic modifications of the genome to control regulator and signature gene expression. By analysing the global expression profiles of hematopoietic stem cells (HSCs), in vivo differentiated CD4+ T cells and CD19+ B cells as well as in vitro differentiated erythrocyte precursor cells, we identified hundreds of transcripts showing type-specific expression in these cell types. To understand the epigenomic changes related to tissue-specific expression during HSC differentiation, we examined the genome-wide distribution of H3K4me1, H3K4me3, H3K27me1, H3K27me3, histone variant H2A.Z, chromatin remodeler BRG1, and RNA Polymerase II in the same four cell types, as well as embryonic stem cells. Analysis of these datasets revealed that numerous key differentiation genes are primed for expression by Brg1 and Pol II binding, as well as bivalent modifications in the HSCs prior to their expression in downstream differentiated cell types. Much of this bivalency in HSC is retained from embryonic stem cells. After differentiation, these modified regions resolve to active chromatin modification configuration in the specific lineage, while in parallel differentiated lineages the bivalent modification remains; Pol II and Brg1 are lost in closer lineages but bivalency resolves to silent monovalency in more distant lineages. Correlation of tissue-specific gene expression with the epigenomic changes predicts tens of thousands of potential common enhancers and tissue-specific enhancers, which may critically contribute to the expression patterns. We provide a valuable dataset for further understanding the regulatory mechanisms of differentiation and function of blood lineages. ChIP-Seq: profiling of DNA-associated proteins in blood cell subsets.

2013-03-25 | E-GEOD-39538 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data